The impact of 21‐Gene Recurrence Score test and classic clinical‐pathologic factors in guiding adjuvant therapy for HER‐2 negative, ER‐positive, early‐stage breast cancer: A retrospective study

Abstract

Both adjuvant hormonal therapy (HT) and chemotherapy (CT) improve survival for women with early-stage breast cancer (ESBC) though recurrence risk reduction is small, and most patients do won't not benefit from CT it. 1 The 21-gene Oncotype DX Breast Recurrence Score ® test (Oncotype DX, Genomic Health, Inc,